MapLight Therapeutics Closes Oversubscribed $372.5 Million Series D

Reston – July 28, 2025 – Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, novel therapies for patients with central nervous system disorders, on its oversubscribed $372.5 million Series D financing. Forbion and Life Sciences at Goldman Sachs Alternatives co-led the round, with additional participation from new investors Sanofi, accounts advised by T. Rowe Price Investment Management and Avego BioScience Capital. The round also included strong participation from existing investors, including funds managed by Novo Holdings, 5AM Ventures, Blue Owl Healthcare Opportunities and others.

Lawyers Christian Plaza, Matthew Schwee, David Brinton, Heather McShea, Michael Tuscan and Jason Valentine led the Cooley team advising MapLight.

Cooley has worked with MapLight since its inception and previously advised the company on its oversubscribed $225 million Series C in November 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.